Marché mondial des médicaments contre l’angiofibrome – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et taille du marché des médicaments contre l'angiofibrome

Le marché des médicaments contre l'angiofibrome devrait connaître une croissance significative au cours de la période de prévision. Les angiofibromes sont causés par une prolifération locale de fibroblastes, de collagène et de vaisseaux sanguins. Dans la sclérose tubéreuse, des mutations existent dans le complexe 1 de la sclérose tubéreuse (TSC1), qui code la protéine hamartine, et dans le complexe 2 de la sclérose tubéreuse (TSC2), qui code la protéine tubérine. Le traitement le plus courant de l'angiofibrome est la chirurgie. Les médicaments contre l'angiofibrome sont essentiels pour traiter l'angiofibrome à un rythme plus rapide.

Data Bridge Market Research analyse le taux de croissance du marché des médicaments contre l'angiofibrome au cours de la période de prévision 2023-2030. Le TCAC attendu du marché des médicaments contre l'angiofibrome a tendance à être d'environ 7 % au cours de la période de prévision mentionnée. Le marché était évalué à 3 milliards USD en 2022 et devrait atteindre 5,15 milliards USD d'ici 2030. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe de Data Bridge Market Research comprend également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des médicaments contre l'angiofibrome

Définition du marché

Angiofibroma is typically categorized as a group of lesions which includes fibrous papule, facial angiofibroma, adenoma sebaceum, periungual fibroma, pearly penile papule and Koenen's tumor. It is a benign vascular neoplasm nasal cavity tumour that is composed of dermal fibrous blood vessels. These diseases are usually diagnosed between the age group of 10 and 19 years old.  It is normally caused by the local overgrowth of fibroblasts, collagen, and blood vessels. Therefore, the early diagnosis and treatment is the most vital step for the diseases prevention.

Global Angiofibroma Drugs Market Dynamics

Drivers

• Growing Cases of Angiofibroma

The increasing inicidence of angiofibroma results for around 0.05% of all head and neck tumors. A frequency of 1:5,000-1:60,000 in otolaryngology patients has been witnessed. Thus, this boosts the market growth.

• Huge Demand For Diagnostic Tests

The increasing demand of several diagnostic tests such as genetic screening, skin biopsy, histopathology tests are driving the growth of the market.

Opportunities

• Increasing Demand for Retail Pharmacies

Increase in the number of angiofibroma drugs being delivered through these retail pharmacies and rise in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Furthermore, patients prefer retail pharmacies for purchasing drugs, as these are easily available.

Restraints/Challenges

• Side Effects of angiofibroma drugs

There are several side effects that are associated with angiofibroma drugs. Angiofibroma drugs can lead to itchiness and may also bleed. Those associated with genetic syndromes result in facial disfigurement and stigmatization.

• High Cost

The huge expenditure of the treatment methods hamper the market growth. Several treatment options such as excision, cryotherapy, topical rapamycin, beta blockers are not so cost-effective and thus hinder the growth of the market.

This angiofibroma drugs market  report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the angiofibroma drugs market  contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Angiofibroma Drugs Market Scope

The angiofibroma drugs market  is segmented on the basis of treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Excision
• Dermabrasion
• Beta Blockers Medication
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Angiofibroma Drugs Market Regional Analysis/Insights

The angiofibroma drugs market  is analyzed and market size insights and trends are provided by treatment, distribution channel and end-user as referenced above.

The major countries covered in the angiofibroma drugs market  report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the presence of key manufacturers of the product is high and, increasing research and development activities, healthcare expenditure.

Asia-Pacific dominates the market due to increased new research and developments.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Angiofibroma Drugs Market Share Analysis

The angiofibroma drugs market  competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to angiofibroma drugs market.

Key players operating in the angiofibroma drugs market  include:

• Galderma (Switzerland)
• Abbvie, Inc. (U.S.)
• Bausch Health Companies Inc. (Canada )
• Bristol Myers Squibb Company (U.S.)
• GSK Plc. (U.K.)
• LEO Pharma A/S (Denmark)
• Novartis AG (Switzerland)
• Fresenius Kabi AG (Germany)
• Merck KGaA (Germany)
• Sanofi (France)

SKU-56901